第2天（主席会议）#ESMO26
1. INTerpath001：黑色素瘤中的 mRNA 疫苗
2. VOLGA：Durva+EV 治疗 MIBC
3. DASLHiCaP：Dara+ADT+RT 治疗前列腺癌
4. DeLLphi305：Tarla+Durva 治疗 ES-SCLC
#OncTwitter @myESMO #gusm #lcsm @OncoAlert @OncUpdates @DanaFarber @sands_jacob @tompowles1
1/5
842 浏览 · 11 赞 · 8 转发 · 4 回复
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgThe #ESMO26 Presidential Symposium is about to begin! 🔥 Super excited to hear the highly anticipated results of the VOLGA trial, presented by the the only and only @tompowles1! @myESMO @apolo_andrea @Uromigos @brian_rini @OncoAlert @LosUromigos @uromigosjapan @MichvdHeijden在 X 查看被引用的帖子
- Oncology Brothers@OncBrothers
4. DeLLphi305: PhIII, Tarlatamab + Durva vs Durva alone as 1L maintenance after chemo-IO in ES-SCLC (n=563): - mOS: 21.1 vs 12.7 mos (HR 0.42) - 12-mo OS: 79.4% vs 53.3% - mPFS: 7.4 vs 1.9 mo (HR 0.34) - ORR: 26.4% vs 4.1% - G≥3 AEs: 46.8% vs 40.6%; CRS 49.6% - New SoC! 5/5
- Oncology Brothers@OncBrothers
3. DASL-HiCaP: PhIII, Darolutamide + ADT + RT in very high-risk PCa (n=1106, incl BCR post-RP) - 4y MFS-CI 95% vs 88% (HR 0.42) - OS immature - ARPIs will play a bigger role in early prostate cancer (DASL-HiCaP & PROTEUS) 4/5
- Oncology Brothers@OncBrothers
2. VOLGA: PhIII, PeriOp Durva ± Treme + NeoAdj EV vs control in cis-ineligible/refusing MIBC: - Durva + EV: 2yr EFS 64% vs 45% (HR 0.51) - 2yr OS 78% vs 69% (HR 0.58) - pCR 45% vs 10%. New SoC - G3/4 AEs 30% (D+EV), 42% (+Treme) 3/5
- Oncology Brothers@OncBrothers
1. INTerpath001: Adj intismeran (mRNA neoantigen) + pembro vs pembro alone in resected stage IIB-IV melanoma: - 2yr RFS 82.2% vs 70% (HR 0.58) - 2yr DMFS 88.5% vs 80.2% (HR 0.62) - First positive PhIII personalized mRNA vaccine!! OS immature. 2/5
来源：Oncology Brothers · x.com